Crescita Begin Period Cash Flow from 2010 to 2026
| CTX Stock | CAD 0.49 0.02 4.26% |
Begin Period Cash Flow | First Reported 2015-03-31 | Previous Quarter 8.5 M | Current Value 8.2 M | Quarterly Volatility 6.1 M |
Check Crescita Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Crescita Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.2 M, Interest Expense of 55.6 K or Selling General Administrative of 10.5 M, as well as many indicators such as Price To Sales Ratio of 0.62, Dividend Yield of 0.0 or PTB Ratio of 0.67. Crescita financial statements analysis is a perfect complement when working with Crescita Therapeutics Valuation or Volatility modules.
Crescita | Begin Period Cash Flow |
Evaluating Crescita Therapeutics's Begin Period Cash Flow across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Crescita Therapeutics's fundamental strength.
Latest Crescita Therapeutics' Begin Period Cash Flow Growth Pattern
Below is the plot of the Begin Period Cash Flow of Crescita Therapeutics over the last few years. It is the amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities. Crescita Therapeutics' Begin Period Cash Flow historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Crescita Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Begin Period Cash Flow | 10 Years Trend |
|
Begin Period Cash Flow |
| Timeline |
Crescita Begin Period Cash Flow Regression Statistics
| Arithmetic Mean | 5,921,091 | |
| Geometric Mean | 2,978,964 | |
| Coefficient Of Variation | 82.20 | |
| Mean Deviation | 4,402,546 | |
| Median | 7,943,800 | |
| Standard Deviation | 4,867,079 | |
| Sample Variance | 23.7T | |
| Range | 13.8M | |
| R-Value | 0.82 | |
| Mean Square Error | 8.4T | |
| R-Squared | 0.67 | |
| Significance | 0.000063 | |
| Slope | 787,181 | |
| Total Sum of Squares | 379T |
Crescita Begin Period Cash Flow History
About Crescita Therapeutics Financial Statements
Crescita Therapeutics investors utilize fundamental indicators, such as Begin Period Cash Flow, to predict how Crescita Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Begin Period Cash Flow | 10.8 M | 7.9 M |
Other Information on Investing in Crescita Stock
Crescita Therapeutics financial ratios help investors to determine whether Crescita Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Crescita with respect to the benefits of owning Crescita Therapeutics security.